IMMP Immutep

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

Media Release

SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, will participate in The JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022.

Presentation Details:

Date:        Wednesday, 7 December 2022                 

Time:        11:20am EST                 

Mr. Voigt will be available for virtual one-on-one meetings during the conference. A live webcast of his presentation will be available and after the meeting within the Investors & Media section of Immutep’s website.

About Immutep

Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immutep’s lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268;

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (917) 679 9282; 



EN
02/12/2022

Underlying

IMMPImmutep

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immutep

 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Quarterly Activities Report Q4 FY25

Immutep Quarterly Activities Report Q4 FY25 Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countriesTrial-in-Progress poster for TACTI-004 presented at the 2025 American Society for Clinical Oncology (ASCO) Annual MeetingNovel combination of efti with KEYTRUDA® (pembrolizumab) and chemotherapy in INSIGHT-003 trial achieves high response rate of 60.8% and 90.2% disease control rate (N=51) in 1L NSCLC In high unmet need patients ...

July 30, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2...

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from 6-9 September 2025. The Trial in Progress poster includes an overview and study design of the TACTI-0...

July 29, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Announces Abstracts Accepted for Presentation at the European ...

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (efti), have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 taking place 17-21 October in Berlin, Germany. A Proffered Pape...

July 28, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Announces Positive Update from Phase I Study of IMP761, a Firs...

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kgThe substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseasesSingle ascending dose levels will continue with 2.5, 7 and 14 mg/kgAdditional data from the Phase I to follow in second half of CY2025  SYDNEY, AUSTRALIA, June 23, 2025 ...

June 23, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Pri...

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planned for presentation at a future medical meeting  SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiate...

May 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch